ACRS:NSD-Aclaris Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.69

Change

+0.18 (+1.44)%

Market Cap

USD 0.75B

Volume

0.28M

Avg Analyst Target

USD 28.00 (+120.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aclaris Therapeutics Inc (ACRS) Stock Analysis:
Based on the Aclaris Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Aclaris Therapeutics Inc is USD 28.00 over the next 12 months. Aclaris Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aclaris Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Aclaris Therapeutics Inc’s stock price was USD 12.69. Aclaris Therapeutics Inc’s stock price has changed by -0.71 % over the past week, -3.79 % over the past month and +255.46 % over the last year.

About

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a researc ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-9.12 (-2.94%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

-0.99 (-0.30%)

USD85.30B 11.13 8.07
REGN Regeneron Pharmaceuticals Inc

+3.41 (+0.54%)

USD70.38B 10.09 8.03
VRTX Vertex Pharmaceuticals Incorpo..

-0.55 (-0.27%)

USD48.34B 24.59 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-6.11 (-1.74%)

USD33.10B N/A N/A
SGEN Seagen Inc

+0.42 (+0.27%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.54 (-1.42%)

USD25.19B 58.75 6.30
ALNY Alnylam Pharmaceuticals Inc

+2.92 (+1.62%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 96.14% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 96.14% 93% A 94% A
Trailing 12 Months  
Capital Gain 255.46% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 255.46% 96% A 97% A+
Trailing 5 Years  
Capital Gain -56.94% 37% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.94% 37% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 224.03% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 224.03% 94% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 589.24% 5% F 3% F
Risk Adjusted Return 38.02% 65% D 54% F
Market Capitalization 0.75B 71% C- 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.47 46% F 37% F
Price / Cash Flow Ratio -19.45 77% C+ 80% B-
EV/EBITDA 0.05 88% B+ 97% A+
Management Effectiveness  
Return on Equity -63.46% 44% F 24% F
Return on Invested Capital -85.83% 24% F 9% F
Return on Assets -21.71% 60% D- 18% F
Debt to Equity Ratio 28.29% 34% F 51% F
Technical Ratios  
Short Ratio 4.77 48% F 30% F
Short Percent 3.62% 55% F 41% F
Beta 0.47 82% B- 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector